{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:26:11Z","timestamp":1787660771461,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Purpose of this study is to evaluate the value of a routinely available baseline SSTR-PET imaging parameter, the Krenning score (KS), within integrated biomarker models for overall survival prediction in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients undergoing peptide receptor radionuclide therapy (PRRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 178 patients with GEP-NET who underwent PRRT. At baseline, the KS, clinical, histopathological, and laboratory parameters were integrated and correlated with OS. OS predictors were identified using univariate Cox regression analysis and incorporated into multivariate models. Model performance was assessed using the concordance index (C-index) and Akaike information criterion (AIC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In univariate analysis, the following parameters were significantly associated with shorter OS: KS 3 vs. KS 4 (p\u2009=\u20090.042), CgA\u2009&gt;\u2009155 ng\/mL (p\u2009=\u20090.003), NSE\u2009&gt;\u200935 ng\/mL (p\u2009=\u20090.042), BMI\u2009&lt;\u200918.5 kg\/m\u00b2 (p\u2009=\u20090.017), CRP\u2009&gt;\u20090.5 mg\/dL (p\u2009=\u20090.045), albumin\u2009&lt;\u20094.1 g\/dL (p\u2009=\u20090.017), and Hb\u2009&lt;\u200912 g\/dL (p\u2009=\u20090.017). The multivariate Cox regression model including KS, hemoglobin, and NSE showed the lowest AIC (C-index\u2009=\u20090.64, CI: 0.57\u20130.71; AIC\u2009=\u2009527.60), while the model incorporating BMI, hemoglobin, and CgA demonstrated the highest C-index (C-index\u2009=\u20090.66, CI: 0.60\u20130.72; AIC\u2009=\u2009582.82).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrated baseline biomarker models combining clinical, laboratory, and imaging parameters may support overall survival risk stratification in GEP-NET patients undergoing PRRT. Incorporation of the routinely available Krenning score contributed to one of the best-performing parsimonious exploratory multivariable models, suggesting that accessible molecular imaging parameters may complement established baseline biomarkers. These exploratory findings require validation in larger, preferably multicenter, independent cohorts before clinical implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01113-w","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:36:09Z","timestamp":1787654169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Krenning score enhances integrated biomarker models for survival prediction in PRRT-treated GEP-NET: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6680-1545","authenticated-orcid":false,"given":"Christian A.","family":"Dascalescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix L.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Fusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz L.","family":"Schnitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias P.","family":"Fabritius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schmid-Tannwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Wenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph J.","family":"Auernhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kn\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Burkard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"R\u00fcbenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice M.","family":"Heimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"1113_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1267\/ahc.12006","volume":"45","author":"G Mizutani","year":"2012","unstructured":"Mizutani G, Nakanishi Y, Watanabe N, et al. Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry. Acta Histochem Cytochem. 2012;45:167\u201376.","journal-title":"Acta Histochem Cytochem"},{"key":"1113_CR2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00259-011-1846-5","volume":"38","author":"D Kaemmerer","year":"2011","unstructured":"Kaemmerer D, Peter L, Lupp A, et al. Molecular imaging with (6)(8)Ga-SSTR PET\/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:1659\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR3","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1007\/s00259-019-04448-8","volume":"46","author":"H Ilhan","year":"2019","unstructured":"Ilhan H, Todica A, Lindner S, et al. First-in-human (18)F-SiFAlin-TATE PET\/CT for NET imaging and theranostics. Eur J Nucl Med Mol Imaging. 2019;46:2400\u20131.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR4","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2967\/jnumed.114.149583","volume":"56","author":"S Niedermoser","year":"2015","unstructured":"Niedermoser S, Chin J, Wangler C, et al. In Vivo Evaluation of (1)(8)F-SiFAlin-Modified TATE: A Potential Challenge for (6)(8)Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. J Nucl Med. 2015;56:1100\u20135.","journal-title":"J Nucl Med"},{"key":"1113_CR5","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864\u201370.","journal-title":"J Nucl Med"},{"key":"1113_CR6","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, et al. (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363.","journal-title":"Lancet Oncol"},{"key":"1113_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1186\/s12885-019-6000-y","volume":"19","author":"S Rudisile","year":"2019","unstructured":"Rudisile S, Gosewisch A, Wenter V, et al. Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer. 2019;19:788.","journal-title":"BMC Cancer"},{"key":"1113_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1245\/s10434-024-16463-7","volume":"32","author":"LC Borbon","year":"2025","unstructured":"Borbon LC, Sherman SK, Breheny PJ, et al. Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2025;32:1136\u201348.","journal-title":"Ann Surg Oncol"},{"key":"1113_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017;105:295\u2013309.","journal-title":"Neuroendocrinology"},{"key":"1113_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000458155","volume":"105","author":"U Knigge","year":"2017","unstructured":"Knigge U, Capdevila J, Bartsch DK, et al. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017;105:310\u20139.","journal-title":"Neuroendocrinology"},{"key":"1113_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000457956","volume":"105","author":"A Perren","year":"2017","unstructured":"Perren A, Couvelard A, Scoazec JY, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology. 2017;105:196\u2013200.","journal-title":"Neuroendocrinology"},{"key":"1113_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2967\/jnumed.119.240911","volume":"61","author":"TA Hope","year":"2020","unstructured":"Hope TA, Bodei L, Chan JA, et al. NANETS\/SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020;61:222\u20137.","journal-title":"J Nucl Med"},{"key":"1113_CR13","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/S1470-2045(15)00186-2","volume":"16","author":"K Oberg","year":"2015","unstructured":"Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435\u201346.","journal-title":"Lancet Oncol"},{"key":"1113_CR14","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00330-012-2510-6","volume":"22","author":"GP Krestin","year":"2012","unstructured":"Krestin GP, Grenier PA, Hricak H, et al. Integrated diagnostics: proceedings from the 9th biennial symposium of the International Society for Strategic Studies in Radiology. Eur Radiol. 2012;22:2283\u201394.","journal-title":"Eur Radiol"},{"key":"1113_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1148\/radiol.2017170062","volume":"285","author":"CF Lundstr\u00f6m","year":"2017","unstructured":"Lundstr\u00f6m CF, Gilmore HL, Ros PR. Integrated Diagnostics: The Computational Revolution Catalyzing Cross-disciplinary Practices in Radiology, Pathology, and Genomics. Radiology. 2017;285:12\u20135.","journal-title":"Radiology"},{"key":"1113_CR16","doi-asserted-by":"crossref","unstructured":"Werner RA, Higuchi T, Pomper MG, Rowe SP. Theranostics in oncology\u2014thriving, now more than ever. Diagnostics (Basel). 2021;11.","DOI":"10.3390\/diagnostics11050805"},{"key":"1113_CR17","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.7150\/thno.112588","volume":"15","author":"FL Herr","year":"2025","unstructured":"Herr FL, Dascalescu C, Ebner R, et al. Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025;15:6444\u201353.","journal-title":"Theranostics"},{"key":"1113_CR18","doi-asserted-by":"publisher","first-page":"101129","DOI":"10.1016\/j.currproblcancer.2024.101129","volume":"52","author":"N Mallak","year":"2024","unstructured":"Mallak N, Yilmaz B, Meyer C, et al. Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies. Curr Probl Cancer. 2024;52:101129.","journal-title":"Curr Probl Cancer"},{"key":"1113_CR19","doi-asserted-by":"publisher","first-page":"1514792","DOI":"10.3389\/fendo.2025.1514792","volume":"16","author":"A Singh","year":"2025","unstructured":"Singh A, Sanduleanu S, Kulkarni HR, Langbein T, Lambin P, Baum RP. The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy. Front Endocrinol (Lausanne). 2025;16:1514792.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1113_CR20","doi-asserted-by":"publisher","first-page":"1169970","DOI":"10.3389\/fmed.2023.1169970","volume":"10","author":"NF Trautwein","year":"2023","unstructured":"Trautwein NF, Schwenck J, Jacoby J, et al. Long-term prognostic factors for PRRT in neuroendocrine tumors. Front Med (Lausanne). 2023;10:1169970.","journal-title":"Front Med (Lausanne)"},{"key":"1113_CR21","doi-asserted-by":"publisher","first-page":"1270421","DOI":"10.3389\/fendo.2023.1270421","volume":"14","author":"V Vukomanovic","year":"2023","unstructured":"Vukomanovic V, Nedic KV, Radojevic MZ, et al. Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience. Front Endocrinol (Lausanne). 2023;14:1270421.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1113_CR22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268621","author":"FL Herr","year":"2025","unstructured":"Herr FL, Dascalescu C, Fabritius MP, et al. PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.124.268621.","journal-title":"J Nucl Med"},{"key":"1113_CR23","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s002590100502","volume":"28","author":"WA Breeman","year":"2001","unstructured":"Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421\u20139.","journal-title":"Eur J Nucl Med"},{"key":"1113_CR24","first-page":"2017","volume":"15","author":"J Wulff","year":"2017","unstructured":"Wulff J, Ejlskov L. Multiple Imputation by Chained Equations in Praxis: Guidelines and Review. Electron J Bus Res Methods. 2017;15:2017\u201358.","journal-title":"Electron J Bus Res Methods"},{"key":"1113_CR25","doi-asserted-by":"publisher","first-page":"Article27","DOI":"10.2202\/1544-6115.1302","volume":"6","author":"GH Green","year":"2007","unstructured":"Green GH, Diggle PJ. On the operational characteristics of the Benjamini and Hochberg False Discovery Rate procedure. Stat Appl Genet Mol Biol. 2007;6:Article27.","journal-title":"Stat Appl Genet Mol Biol"},{"key":"1113_CR26","doi-asserted-by":"crossref","unstructured":"Cavanaugh JE, Neath AA. The Akaike information criterion: background, derivation, properties, application, interpretation, and refinements. WIREs Comput Stat. 2019;11.","DOI":"10.1002\/wics.1460"},{"key":"1113_CR27","doi-asserted-by":"publisher","first-page":"103496","DOI":"10.1016\/j.jbi.2020.103496","volume":"108","author":"E Longato","year":"2020","unstructured":"Longato E, Vettoretti M, Di Camillo B. A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models. J Biomed Inf. 2020;108:103496.","journal-title":"J Biomed Inf"},{"key":"1113_CR28","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, et al. Quantitative (68)Ga-DOTATATE PET\/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with (177)Lu-DOTATATE. J Nucl Med. 2021;62:1406\u201314.","journal-title":"J Nucl Med"},{"key":"1113_CR29","doi-asserted-by":"crossref","unstructured":"Zwirtz K, Hardt J, Acker G, et al. Comparison of Choi, RECIST and somatostatin receptor PET\/CT based criteria for the evaluation of response and response prediction to PRRT. Pharmaceutics. 2022;14.","DOI":"10.3390\/pharmaceutics14061278"},{"key":"1113_CR30","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1007\/s00259-024-06767-x","volume":"51","author":"V Santoro-Fernandes","year":"2024","unstructured":"Santoro-Fernandes V, Schott B, Deatsch A, et al. Models using comprehensive, lesion-level, longitudinal [(68)Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [(177)Lu]Lu-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2024;51:3428\u201339.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2967\/jnumed.123.265987","volume":"65","author":"M Mileva","year":"2024","unstructured":"Mileva M, Marin G, Levillain H, et al. Prediction of (177)Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. J Nucl Med. 2024;65:236\u201344.","journal-title":"J Nucl Med"},{"key":"1113_CR32","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","volume":"49","author":"A Sundl\u00f6v","year":"2022","unstructured":"Sundl\u00f6v A, Gleisner KS, Tennvall J, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49:3830\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00259-023-06383-1","volume":"51","author":"D Wild","year":"2023","unstructured":"Wild D, Gr\u00f8nb\u00e6k H, Navalkissoor S, et al. A phase I\/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2023;51:183\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR34","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1007\/s00259-024-06682-1","volume":"51","author":"SB Sch\u00fcrrle","year":"2024","unstructured":"Sch\u00fcrrle SB, Eberlein U, Ansquer C, et al. Dosimetry and pharmacokinetics of [(177)Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2024;51:2428\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR35","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.7150\/thno.25919","volume":"8","author":"H Wang","year":"2018","unstructured":"Wang H, Cheng Y, Zhang J, et al. Response to Single Low-dose (177)Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. Theranostics. 2018;8:3308\u201316.","journal-title":"Theranostics"},{"key":"1113_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00259-024-06863-y","volume":"52","author":"M Maccauro","year":"2024","unstructured":"Maccauro M, Cuomo M, Bauckneht M, et al. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [(177)Lu]Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2024;52:291\u2013304.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1113_CR37","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/bjc.1998.635","volume":"78","author":"E Baudin","year":"1998","unstructured":"Baudin E, Gigliottil A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998;78(8):1102\u20137.","journal-title":"Br J Cancer"},{"key":"1113_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.113.125336","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55:183\u201390.","journal-title":"J Nucl Med"},{"key":"1113_CR39","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1055\/a-1672-4653","volume":"53","author":"R Halperin","year":"2021","unstructured":"Halperin R, Ahron-Hananel G, Badarna M, et al. Plasma Hemoglobin and Red Blood Cell Mass Levels as Dynamic Prognostic Markers for Progression and Survival in Pancreatic Neuroendocrine Tumors. Horm Metab Res. 2021;53:810\u20137.","journal-title":"Horm Metab Res"},{"key":"1113_CR40","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","volume":"17","author":"IM Modlin","year":"2010","unstructured":"Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A\u2013biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427\u201343.","journal-title":"Ann Surg Oncol"},{"key":"1113_CR41","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968\u201377.","journal-title":"Lancet"},{"key":"1113_CR42","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.7150\/thno.98053","volume":"14","author":"A Akhavanallaf","year":"2024","unstructured":"Akhavanallaf A, Joshi S, Mohan A, et al. Enhancing precision: A predictive model for (177)Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative (68)Ga-DOTATATE PET and clinicopathological biomarkers. Theranostics. 2024;14:3708\u201318.","journal-title":"Theranostics"},{"key":"1113_CR43","doi-asserted-by":"crossref","unstructured":"Malau IA, Chang JP, Lin YW, Chang CC, Chiu WC, Su KP. Omega-3 fatty acids and neuroinflammation in depression: targeting damage-associated molecular patterns and neural biomarkers. Cells. 2024;13.","DOI":"10.3390\/cells13211791"},{"key":"1113_CR44","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1089\/089771501300227297","volume":"18","author":"UE Pleines","year":"2001","unstructured":"Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, Kossmann T. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma. 2001;18:491\u20138.","journal-title":"J Neurotrauma"},{"key":"1113_CR45","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1039\/D3AN01602A","volume":"149","author":"M Ayd\u0131n","year":"2024","unstructured":"Ayd\u0131n M, Ayd\u0131n EB, Sezgint\u00fcrk MK. Ultrasensitive detection of NSE employing a novel electrochemical immunosensor based on a conjugated copolymer. Analyst. 2024;149:1632\u201344.","journal-title":"Analyst"},{"key":"1113_CR46","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1373\/clinchem.2011.176099","volume":"58","author":"PR Bech","year":"2012","unstructured":"Bech PR, Ramachandran R, Dhillo WS, Martin NM, Bloom SR. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript. Clin Chem. 2012;58:941\u20133.","journal-title":"Clin Chem"},{"key":"1113_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000321535","volume":"84","author":"I Pregun","year":"2011","unstructured":"Pregun I, Hersz\u00e9nyi L, Juh\u00e1sz M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion. 2011;84:22\u20138.","journal-title":"Digestion"},{"key":"1113_CR48","doi-asserted-by":"publisher","first-page":"e13379","DOI":"10.1111\/jne.13379","volume":"37","author":"D Papantoniou","year":"2025","unstructured":"Papantoniou D, Fr\u00f6ss-Baron K, Garske-Rom\u00e1n U, et al. Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients. J Neuroendocrinol. 2025;37:e13379.","journal-title":"J Neuroendocrinol"},{"key":"1113_CR49","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2967\/jnumed.118.224386","volume":"60","author":"EA Aalbersberg","year":"2019","unstructured":"Aalbersberg EA, Huizing DMV, Walraven I, et al. Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients. J Nucl Med. 2019;60:1259\u201365.","journal-title":"J Nucl Med"},{"key":"1113_CR50","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/PAS.0b013e31821a0696","volume":"35","author":"Z Yang","year":"2011","unstructured":"Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853\u201360.","journal-title":"Am J Surg Pathol"},{"key":"1113_CR51","doi-asserted-by":"crossref","unstructured":"Varghese DG, Del Rivero J, Bergsland E. Grade progression and intrapatient tumor heterogeneity as potential contributors to resistance in gastroenteropancreatic neuroendocrine tumors. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15143712"},{"key":"1113_CR52","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. (111)In-Pentetreotide Scintigraphy Versus (68)Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med. 2019;60:1266\u20139.","journal-title":"J Nucl Med"},{"key":"1113_CR53","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","volume":"36","author":"A Haug","year":"2009","unstructured":"Haug A, Auernhammer CJ, W\u00e4ngler B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR54","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2967\/jnumed.121.263703","volume":"64","author":"B Saboury","year":"2023","unstructured":"Saboury B, Bradshaw T, Boellaard R, et al. Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem. J Nucl Med. 2023;64:188\u201396.","journal-title":"J Nucl Med"},{"key":"1113_CR55","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1007\/s00259-019-04455-9","volume":"46","author":"A Toriihara","year":"2019","unstructured":"Toriihara A, Baratto L, Nobashi T, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET\/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46:2244\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR56","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.121.262652","volume":"63","author":"P Thuillier","year":"2022","unstructured":"Thuillier P, Liberini V, Grimaldi S, et al. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from (68)Ga-DOTATOC PET\/CT in Well-Differentiated Neuroendocrine Tumors. J Nucl Med. 2022;63:1014\u201320.","journal-title":"J Nucl Med"},{"key":"1113_CR57","doi-asserted-by":"crossref","unstructured":"Urso L, Castello A, Treglia G, et al. Relevance of volumetric parameters applied to [^68Ga]Ga-DOTATOC PET\/CT in NET patients treated with PRRT. Diagnostics (Basel). 2023;13.","DOI":"10.3390\/diagnostics13040606"},{"key":"1113_CR58","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s13244-018-0645-y","volume":"9","author":"F Pesapane","year":"2018","unstructured":"Pesapane F, Volont\u00e9 C, Codari M, Sardanelli F. Artificial intelligence as a medical device in radiology: ethical and regulatory issues in Europe and the United States. Insights Imaging. 2018;9:745\u201353.","journal-title":"Insights Imaging"},{"key":"1113_CR59","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jacr.2017.12.026","volume":"15","author":"JH Thrall","year":"2018","unstructured":"Thrall JH, Li X, Li Q, et al. Artificial Intelligence and Machine Learning in Radiology: Opportunities, Challenges, Pitfalls, and Criteria for Success. J Am Coll Radiol. 2018;15:504\u20138.","journal-title":"J Am Coll Radiol"},{"key":"1113_CR60","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00259-012-2123-y","volume":"39","author":"L Kabasakal","year":"2012","unstructured":"Kabasakal L, Demirci E, Ocak M, et al. Comparison of \u2076\u2078Ga-DOTATATE and \u2076\u2078Ga-DOTANOC PET\/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1113_CR61","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2967\/jnumed.112.111724","volume":"54","author":"D Wild","year":"2013","unstructured":"Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364\u201372.","journal-title":"J Nucl Med"},{"key":"1113_CR62","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1021\/acs.bioconjchem.5b00510","volume":"26","author":"S Litau","year":"2015","unstructured":"Litau S, Niedermoser S, Vogler N, et al. Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics. Bioconjug Chem. 2015;26:2350\u20139.","journal-title":"Bioconjug Chem"},{"key":"1113_CR63","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.113.126177","volume":"55","author":"I Velikyan","year":"2014","unstructured":"Velikyan I, Sundin A, S\u00f6rensen J, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55:204\u201310.","journal-title":"J Nucl Med"},{"key":"1113_CR64","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","volume":"47","author":"H Ilhan","year":"2020","unstructured":"Ilhan H, Lindner S, Todica A, et al. Biodistribution and first clinical results of (18)F-SiFAlin-TATE PET: a novel (18)F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47:870\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01113-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01113-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01113-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:03:03Z","timestamp":1787659383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01113-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01113-w","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective single-center study involving human participants and human data was approved by the local institutional review board of LMU Munich, Germany, approval number 19\u2013027. The requirement for informed consent was waived due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"112"}}